Drug intelligence / Profile preview

Flt3 ligand

Development stage
Phase 3
Lead developer
Amgen
Modality
Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous
01

Overview

Flt3 ligand (FLT3L) is a hematopoietic cytokine and growth factor that binds to the fms-like tyrosine kinase 3 (FLT3/CD135) receptor on hematopoietic progenitor cells. This interaction induces dimerization and activation of the receptor's intrinsic tyrosine kinase activity, leading to autophosphorylation and downstream signaling through pathways such as STAT5a, ERK1/2, and PI3K[6][8]. FLT3L acts synergistically with other growth factors to stimulate proliferation and mobilization of bone marrow precursor cells—including CD34+ stem cells—and promotes differentiation into dendritic cells as well as B cell and T cell lineages[1][4][7]. Recombinant forms of FLT3L are used experimentally for ex vivo expansion or mobilization of hematopoietic stem/progenitor cells. The protein is structurally homologous to stem cell factor (SCF) and colony stimulating factor 1 (CSF-1)[7].

Brand names
Mobista
Other names
fms-like tyrosine kinase 3 ligandrecombinant flt3 ligandrecombinant human flt-3 ligand
02

Targets

FLT3 (Fms related receptor tyrosine kinase 3)

Beyond the preview

Go deeper on Flt3 ligand.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flt3 ligand.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call